Hennion & Walsh Asset Management, Inc. Uni Qure N.V. Transaction History

Hennion & Walsh Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $55,269 - $83,132	-3,255 Reduced 5.35%	57,588 $1.08 Million
Q2 2022 Jul 19, 2022	SELL	$13.15 - $20.45 $37,175 - $57,812	-2,827 Reduced 4.44%	60,843 $1.13 Million
Q1 2022 Apr 26, 2022	SELL	$14.54 - $21.5 $33,311 - $49,256	-2,291 Reduced 3.47%	63,670 $1.15 Million
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $530,368 - $943,606	-26,204 Reduced 28.43%	65,961 $1.37 Million
Q3 2021 Nov 12, 2021	SELL	$26.01 - $38.22 $63,932 - $93,944	-2,458 Reduced 2.6%	92,165 $2.95 Million
Q2 2021 Aug 13, 2021	SELL	$29.97 - $37.17 $104,085 - $129,091	-3,473 Reduced 3.54%	94,623 $2.91 Million
Q1 2021 May 17, 2021	BUY	$29.24 - $42.03 $2.87 Million - $4.12 Million	98,096 New	98,096 $3.31 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.